Protega collaborates with Wellgistics for Roxybond launch

Privately-held US drugmaker Protega Pharmaceuticals, which recently launched Roxybond (oxycodone hydrochloride), the first and only Food and Drug Administration (FDA)-approved abuse-deterrent immediate-release (IR) pain medication in the USA, is now collaborating with Wellgistics Health (Nasdaq: WGRX) to support pharmacist education on abuse-deterrent pain management options and regulatory compliance as well as increase patient access to the drug for appropriately prescribed patients.

On September 5, 2024, the FDA approved a new 10mg strength of Roxybond, expanding Protega's line of abuse-deterrent IR opioids, which also includes 5mg, 15mg, and 30mg tablet options.

Wellgistics Health is a pharmaceutical wholesaler and National Association of Boards of Pharmacy (NABP) authorized distributor that serves over 5,400 independent pharmacies across all 50 states. The relationship will support education to these pharmacies and help provide distribution of Roxybond to appropriately prescribed patients, particularly in the underserved and rural areas that Wellgistics Health serves where independent pharmacies play a critical role in patient care.